Annual report pursuant to Section 13 and 15(d)

Composition of Certain Financial Statement Captions (Details 1)

v2.4.0.6
Composition of Certain Financial Statement Captions (Details 1) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Technology [Member]
Dec. 31, 2012
Customer relationships [Member]
Dec. 31, 2012
Product registrations [Member]
Dec. 31, 2012
Covenants Not to Compete [Member]
Dec. 31, 2012
Tradename [Member]
Dec. 31, 2012
Other [Member]
Dec. 31, 2012
OPKO Chile [Member]
Dec. 31, 2012
OPKO Chile [Member]
Customer relationships [Member]
Dec. 31, 2012
OPKO Chile [Member]
Product registrations [Member]
Dec. 31, 2012
OPKO Chile [Member]
Tradename [Member]
Dec. 31, 2012
Exakta OPKO [Member]
Dec. 31, 2012
Exakta OPKO [Member]
Customer relationships [Member]
Dec. 31, 2012
Exakta OPKO [Member]
Product registrations [Member]
Dec. 31, 2012
Exakta OPKO [Member]
Covenants Not to Compete [Member]
Dec. 31, 2012
Exakta OPKO [Member]
Tradename [Member]
Dec. 31, 2012
CURNA [Member]
Dec. 31, 2012
CURNA [Member]
In-process research research and development [Member]
Dec. 31, 2012
CURNA [Member]
Other [Member]
Dec. 31, 2012
FineTech [Member]
Dec. 31, 2012
FineTech [Member]
Technology [Member]
Dec. 31, 2012
FineTech [Member]
Customer relationships [Member]
Dec. 31, 2012
FineTech [Member]
Covenants Not to Compete [Member]
Dec. 31, 2012
FineTech [Member]
Tradename [Member]
Dec. 31, 2012
OURLab [Member]
Dec. 31, 2012
OURLab [Member]
Technology [Member]
Dec. 31, 2012
OURLab [Member]
Customer relationships [Member]
Dec. 31, 2012
OURLab [Member]
Covenants Not to Compete [Member]
Dec. 31, 2012
OURLab [Member]
Tradename [Member]
Dec. 31, 2012
OURLab [Member]
Other [Member]
Dec. 31, 2012
OPKO Diagnostics [Member]
Dec. 31, 2012
OPKO Diagnostics [Member]
Technology [Member]
Dec. 31, 2012
Farmadiet [Member]
Dec. 31, 2012
Farmadiet [Member]
Technology [Member]
Dec. 31, 2012
Farmadiet [Member]
In-process research research and development [Member]
Dec. 31, 2012
Farmadiet [Member]
Customer relationships [Member]
Dec. 31, 2012
Farmadiet [Member]
Product registrations [Member]
Dec. 31, 2012
Farmadiet [Member]
Covenants Not to Compete [Member]
Dec. 31, 2012
Farmadiet [Member]
Tradename [Member]
Dec. 31, 2012
SciGen [Member]
Dec. 31, 2012
SciGen [Member]
Technology [Member]
Dec. 31, 2012
SciGen [Member]
Customer relationships [Member]
Fair values assigned to major intangible asset classes upon each acquisition                                                                                      
Total identified intangible assets                 $ 10,806 $ 3,945 $ 5,829 $ 1,032 $ 345 $ 121 $ 77 $ 70 $ 77 $ 10,290 $ 10,000 $ 290 $ 18,800 $ 2,700 $ 14,200 $ 1,500 $ 400 $ 14,030 $ 1,370 $ 3,860 $ 6,900 $ 1,830 $ 70 $ 44,400 $ 44,400 $ 10,798 $ 5,437 $ 1,459 $ 436 $ 2,930 $ 187 $ 349 $ 1,130 $ 1,090 $ 40
Goodwill 80,450 [1] 39,815             5,441       21         4,827     11,623         29,629           17,977   8,062             760    
Total intangible assets acquired                 $ 16,247       $ 366         $ 15,117     $ 30,423         $ 43,659           $ 62,377   $ 18,860             $ 1,890    
Weighted average amortization period     9 years 6 years 9 years 5 years 4 years 4 years                                                                      
[1] As of December 31, 2012, total assets include $5.6 million and total liabilities include $5.5 million related to SciGen (I.L.) Ltd, ("SciGen"), a consolidated variable interest entity. SciGen's consolidated assets are owned by SciGen and SciGen's consolidated liabilities are those as to which there is no recourse against us. Refer to Note 3.